• 1. An artificial photosynthetic system for photoaccumulation of two electrons on a fused dipyridophenazine (dppz)–pyridoquinolinone ligand?
  Philipp Traber,Stephan Kupfer,Stefanie Gr?fe,Isabelle Baussanne,Martine Demeunynck,Jean-Marie Mouesca,Serge Gambarelli,Vincent Artero,Murielle Chavarot-Kerlidou Chem. Sci., 2018,9, 4152-4159
• 2. An amorphous carbon nitride/NiO/CoN-based composite: a highly efficient nonprecious electrode for supercapacitors and the oxygen evolution reaction?
  Huifang Yang,Haoran Guo,Peidong Fan,Xinpan Li,Wenlu Ren,Rui Song Nanoscale, 2020,12, 7024-7034
• 3. Alternative donor substrates for inverting and retaining glycosyltransferases?
  Luke L. Lairson,Warren W. Wakarchuk Chem. Commun., 2007, 365-367
• 4. An apparatus for testing water by measurement of its electrical conductivity
  Analyst, 1912,37, 538-543
• 5. An integrated digital microfluidic chip for multiplexed proteomic sample preparation and analysis by MALDI-MS?
  Hyejin Moon,Aaron R. Wheeler,Robin L. Garrell,Chang-Jin “CJ” Kim Lab Chip, 2006,6, 1213-1219

• Solvents and Organic Chemicals Organic Compounds Organic nitrogen compounds Organonitrogen compounds Amines Primary amines

Introduction to 2-(4-Methyl-1H-pyrazol-1-yl)ethylamine Dihydrochloride (CAS No. 1006458-47-4)

2-(4-Methyl-1H-pyrazol-1-yl)ethylamine Dihydrochloride, identified by the Chemical Abstracts Service Number (CAS No.) 1006458-47-4, is a compound of significant interest in the field of pharmaceutical chemistry and drug discovery. This compound belongs to the pyrazole derivatives, a class of heterocyclic compounds known for their broad spectrum of biological activities. The structural motif of pyrazole, characterized by a five-membered ring containing two nitrogen atoms, makes it a versatile scaffold for medicinal chemistry applications. The presence of a methyl group at the 4-position and an ethylamine substituent at the 2-position further enhances its pharmacological potential.

The dihydrochloride salt form of this compound is particularly relevant in pharmaceutical formulations due to its improved solubility and stability, which are critical factors for drug development. The hydrochloride moiety not only enhances the compound's solubility in aqueous solutions but also contributes to its bioavailability, making it a suitable candidate for further pharmacokinetic studies.

In recent years, pyrazole derivatives have garnered considerable attention in the scientific community due to their diverse biological activities. These compounds have been investigated for their potential applications in various therapeutic areas, including anti-inflammatory, anticancer, antimicrobial, and antiviral treatments. The unique structural features of 2-(4-Methyl-1H-pyrazol-1-yl)ethylamine Dihydrochloride make it an attractive candidate for further exploration in these domains.

One of the most compelling aspects of this compound is its ability to interact with biological targets through multiple mechanisms. The pyrazole ring can engage in hydrogen bonding interactions due to the presence of nitrogen atoms, while the ethylamine side chain provides a hydrophobic surface that can interact with lipid moieties in biological membranes. This dual functionality makes it a promising candidate for designing drugs that require both hydrophilic and hydrophobic interactions with biological targets.

Recent studies have highlighted the potential of 2-(4-Methyl-1H-pyrazol-1-yl)ethylamine Dihydrochloride as an intermediate in the synthesis of more complex pharmacophores. Researchers have utilized this compound to develop novel molecules with enhanced binding affinity and selectivity towards specific biological targets. For instance, modifications of the methyl group at the 4-position and the ethylamine substituent at the 2-position have been explored to optimize pharmacokinetic properties such as metabolic stability and oral bioavailability.

The compound's structural similarity to known bioactive molecules has also facilitated its use in structure-based drug design. By leveraging computational methods such as molecular docking and homology modeling, researchers can predict how 2-(4-Methyl-1H-pyrazol-1-yl)ethylamine Dihydrochloride interacts with target proteins. These insights can guide the development of more potent and selective drugs by identifying key residues involved in binding and optimizing interactions through rational molecular design.

Moreover, the dihydrochloride salt form has been shown to improve the compound's pharmacokinetic profile, making it a more viable candidate for clinical development. Solubility is a critical factor in drug formulation, as it directly impacts bioavailability and therapeutic efficacy. The enhanced solubility provided by the dihydrochloride salt allows for easier administration and potentially higher therapeutic concentrations in vivo.

In conclusion, 2-(4-Methyl-1H-pyrazol-1-yl)ethylamine Dihydrochloride (CAS No. 1006458-47-4) represents a promising compound in pharmaceutical research due to its unique structural features and potential biological activities. Its versatility as a scaffold for drug design, coupled with its improved solubility and stability in its dihydrochloride form, makes it an attractive candidate for further investigation. As research continues to uncover new applications for pyrazole derivatives, compounds like this are poised to play a significant role in the development of next-generation therapeutics.

• 1170137-51-5(2-(4-Methyl-1h-pyrazol-1-yl)propylamine Hydrochloride)
• 1006483-34-6(1-(4-Methyl-1H-pyrazol-1-yl)propan-2-amine)
• 1332529-52-8(4-(Chloromethyl)-1-ethyl-1H-pyrazole hydrochloride)
• 1006469-41-5(2-(4-Methyl-1H-pyrazol-1-yl)ethanol)
• 956758-69-3(3-(4-Methyl-1H-pyrazol-1-yl)propan-1-amine)
• 1006434-01-0(1-Ethyl-1H-pyrazole-4-carbonitrile)
• 130098-90-7(1H-Pyrazole, 4-methyl-1-(1-methylethyl)-)
• 101395-71-5(2-(1H-pyrazol-1-yl)ethan-1-amine)
• 1177297-64-1(N-Methyl-2-(4-methyl-1H-pyrazol-1-yl)ethanamine)
• 856696-09-8((1-Ethyl-1H-pyrazol-4-yl)methanamine)